Advanced search
Publication Cover
Leukemia & Lymphoma Volume 57, 2016 - Issue 11
Submit an article Journal homepage
187
Views
5
CrossRef citations to date
0
Altmetric
Letters to the Editor

No evidence of splenic disease in patients with splenic marginal zone lymphoma undergoing splenectomy for autoimmune hemolytic anemia after monotherapy with rituximab

Christina KalpadakisDepartment of Haematology, Heraklion University Hospital, University of Crete, Crete, Greece; Correspondence[email protected]
,
Gerassimos A. PangalisDepartment of Haematology, Athens Medical Center-Psychikon Branch, Athens, Greece;
,
Sotirios SachanasDepartment of Haematology, Athens Medical Center-Psychikon Branch, Athens, Greece;
,
Demetra RontogianniDepartment of Anatomic Pathology, Evangelismos General Hospital, Athens, Greece;
,
Penelope KorkolopoulouDepartment of Pathology, University of Athens, Athens, Greece;
,
Vassilis MilionisDepartment of Pathology, University of Athens, Athens, Greece;
,
Theodoros P. VassilakopoulosDepartment of Haematology, National and Kapodistrian University of Athens, Laikon General Hospital, Athens, Greece
,
Helen A. PapadakiDepartment of Haematology, Heraklion University Hospital, University of Crete, Crete, Greece;
&
Maria K. AngelopoulouDepartment of Haematology, National and Kapodistrian University of Athens, Laikon General Hospital, Athens, Greece
 show all
Pages 2705-2708 | Received 11 Jan 2016, Accepted 14 Feb 2016, Published online: 15 Apr 2016

References

  • Isaacson PG, Piris MA, Berger F, et al. Splenic B-cell marginal zone lymphoma. In: Swerdlow SH, Campo E, Harris NL, et al., editors. World Health organization classification of tumours: pathology and genetics of tumours of haematopoietic and lymphoid tissues. Lyon: IARC; 2008. p. 185–187.
  • Matutes E, Oscier D, Montalban C, et al. Splenic marginal-zone lymphoma proposals for a revision of diagnostic, staging and therapeutic criteria. Leukemia. 2008;22:487–395.
  • Bennett M, Sharma K, Yegena S, et al. Rituximab monotherapy for splenic marginal zone lymphoma. Haematologica. 2005;90:856–858.
  • Tsimberidou AM, Catovsky D, Schlette E, et al. Outcomes in patients with splenic marginal zone lymphoma and marginal zone lymphoma treated with rituximab with or without chemotherapy or chemotherapy alone. Cancer. 2006;107:125–135.
  • Kalpadakis C, Pangalis GA, Dimopoulou MN, et al. Rituximab monotherapy is highly effective in splenic marginal zone lymphoma. Hematol Oncol. 2007;25:127–131.
  • Kalpadakis C, Pangalis GA, Vassilakopoulos TP, et al. Rituximab monotherapy is the treatment of choice for splenic marginal zone lymphoma (SMZL). Ann Oncol. 2008;19:Abstract #367.
  • Else M, Marin-Niebla A, de la Cruz F, et al. Rituximab, used alone or in combination, is superior to other treatment modalities in splenic marginal zone lymphoma. Br J Haematol. 2012;159:322–328.
  • Kalpadakis C, Pangalis GA, Angelopoulou MK, et al. Treatment of Splenic Marginal Zone Lymphoma with rituximab monotherapy: progress report and comparison with splenectomy. Oncologist. 2013;18:190–197.
  • Kalpadakis C, Pangalis GA, Angelopoulou MK, et al. Validation of the simplified prognostic score for SMZL of the SLSG in a series of patients treated homogeneously with rituximab monotherapy and long term outcome of rituximab responders. 2015Haematologica. 2015;100(s1):269(abstract #P681).
  • Fabbri A, Gozzetti A, Lazzi S, et al. Activity of rituximab monotherapy in refractory splenic marginal zone lymphoma complicated with autoimmune hemolytic anemia. Clin Lymphoma Myeloma. 2006;6:496–499.
  • Paydas S, Yavuz S, Disel U, et al. Successful rituximab therapy for hemolytic anemia associated with relapsed splenic marginal zone lymphoma with leukemic phase. Leuk Lymphoma. 2003;44:2165–2166.
  • Stamatopoulos K, Papadaki T, Pontikoglou C, et al. Lymphocyte subpopulation imbalances, bone marrow hematopoiesis and histopathology in rituximab-treated lymphoma patients with late-onset neutropenia. Leukemia. 2008;22:1446–1449.
  • Thieblemont C, Felman P, Callet-Bauchu E, et al. Splenic marginal-zone lymphoma: a distinct clinical and pathological entity. Lancet Oncol. 2003;4:95–103.
  • Troussard X, Valensi F, Duchayne E, et al. Splenic lymphoma with villous lymphocytes: clinical presentation, biology and prognostic factors in a series of 100 patients. Br J Haematol. 1996;93:731–736.
  • Treon S, Anderson K. The use of rituximab in the treatment of malignant and nonmalignant plasma cell disorders. Semin Oncol. 2000;27:79–85.
  • Andersen MH. Immune regulation by self-recognition: novel possibilities for anticancer immunotherapy. J Natl Cancer Inst. 2015;107::djv154. doi:10.1093/jnci/djv154.
  • Darabi K, Abdel-Wahab O, Dzik WH. Current usage of intravenous immune globulin and the rationale behind it: the Massachusetts General Hospital data and a review of the literature. Transfusion. 2006;46:741–753.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.